1. Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
- Author
-
Chen R, Campbell JL, and Chen B
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Runzhe Chen,1 Jos L Campbell,2,3 Baoan Chen1 1Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China; 2Stanford University Department of Radiology, Molecular Imaging Program at Stanford, Palo Alto, CA, USA; 3Royal Melbourne Institute of Technology, School of Applied Science, Melbourne, VIC, Australia Abstract: Relapse of acute lymphoblastic leukemia remains a major cause of death in patients following allogeneic hematopoietic stem cell transplantation. Several factors may affect the concurrence and outcome of relapse, which include graft-versus-host disease, minimal residual disease or intrinsic factors of the disease, and transplantation characteristics. The mainstay of relapse prevention and treatment is donor leukocyte infusions, targeted therapies, second transplantation, and other novel therapies. In this review, we mainly focus on addressing the impact of graft-versus-host disease on relapse and the prophylaxis and treatment of acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. We also make recommendations for critical strategies to prevent relapse after transplantation and challenges that must be addressed to ensure success. Keywords: acute lymphoblastic leukemia, relapse, allogeneic hematopoietic stem cell transplantation, prevention, therapy
- Published
- 2015